Mechanism of action of the multikinase inhibitor Foretinib.

Archive ouverte

Dufies, Maeva | Jacquel, Arnaud | Robert, Guillaume | Cluzeau, Thomas | Puissant, Alexandre | Fenouille, Nina | Legros, Laurence | Raynaud, Sophie | Cassuto, Jill-Patrice | Luciano, Fréderic | Auberger, Patrick

Edité par CCSD ; Taylor & Francis -

International audience. Mitotic catastrophe (MC) is induced when stressed cells enter prematurely or inappropriately into mitosis and can be caused by ionizing radiation and anticancer drugs. Foretinib is a multikinase inhibitor whose mechanism of action is incompletely understood. We investigated here the effect of Foretinib on chronic myelogenous leukemia (CML) cell lines either sensitive (IM-S) or resistant (IM-R) to the tyrosine kinase inhibitor Imatinib. Foretinib decreased viability and clonogenic potential of IM-S and IM-R CML cells as well. Foretinib-treated cells exhibited increased size, spindle assembly checkpoint anomalies and enhanced ploidy that collectively evoked mitotic catastrophe (MC). Accordingly, Foretinib-stimulated CML cells displayed decreased expression of Cdk1, Cyclin B1 and Plk1. In addition, Foretinib triggered caspase-2 activation that precedes mitochondrial membrane permeabilization. Accordingly, z-VAD-fmk and a caspase-2 siRNA abolished Foretinib-mediated cell death but failed to affect MC, indicating that Foretinib-mediated apoptosis and MC are two independent events. Anisomycin, a JNK activator, impaired Foretinib-induced MC and inhibition or knockdown of JNK phenotyped its effect on MC. Moreover, we found that Foretinib acted as a potent inhibitor of JNK. Importantly, Foretinib exhibited no or very little effect on normal peripheral blood mononuclear cells, monocytes or melanocytes cells but efficiently inhibited the clonogenic potential of CD34+ cell from CML patients. Collectively, our data show that the multikinase inhibitor Foretinib induces MC in CML cells and other cell lines via JNK-dependent inhibition of Plk1 expression and triggered apoptosis by a caspase 2-mediated mechanism. This unusual mechanism of action may have important implications for the treatment of cancer.

Consulter en ligne

Suggestions

Du même auteur

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Archive ouverte | Puissant, Alexandre | CCSD

International audience. Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BCR-ABL. Imatinib, an inhibitor of BCR-ABL, has emerged as the leading compound to treat CML ...

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness

Archive ouverte | Puissant, Alexandre | CCSD

International audience. Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BCR-ABL. Imatinib, an inhibitor of BCR-ABL, has emerged as the leading compound to treat CML ...

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

Archive ouverte | Cluzeau, Thomas | CCSD

International audience. Azacitidine is the leading compound to treat patients suffering myelodysplastic syndrome (MDS) or AML with less than 30% of blasts, but a majority of patients is primary refractory or rapidly...

Chargement des enrichissements...